PPT-NASPCC: Chemotherapy Options for Advanced Prostate Cancer

Jeanny B AragonChing MD FACP Clinical Program Director of Genitourinary Cancers Inova Schar Cancer Institute Associate Professor of Medicine Virginia Commonwealth University October 13 2018. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a . Chapter 16; Pages 797 to 815A. also Section 16.11: Drug Resistance. Folder Title: CxChemoPart1. Updated: . April 23, 2018. Therapeutic Modality Options. Surgery. Radiation: X-Ray; Photodynamic Therapy; Thermal Ablation; Microwave; . ADVANCED PROSTATE CANCER: BONE ISSUES AND METASTASES Samuel Denmeade, MD Professor of Oncology, Urology and Pharmacology The Johns Hopkins University School of Medicine Castrate-sensitive Non-Metastatic th. most incident and lethal cancer. New cases: 225,000 annually. Deaths: 140,000 annually. *Almost 75% of cases present with advanced stage .. *Risk of relapse of advanced stage disease is as high as 70%. The second most common cancer diagnosed in men. The incidence increase with age very rare before age of 40, more in western countries particularly Scandinavian countries (low light exposure), and black men are at greatest risk. Jeanny B. Aragon-Ching, M.D., F.A.C.P.. Clinical Program Director of Genitourinary Cancers, Inova . Schar. Cancer Institute. Associate Professor of Medicine, Virginia Commonwealth University. October 18, 2019. Megan Swanson, MD MPH. Assistant Professor. Gynecologic Oncology. UCSF. Limited effective treatment options for advanced cervical cancer. Problem. : when cervical cancer is . advanced. and/or recurrent . When to Image Based on . Choosing . Wisely. ®. . and ACR Appropriateness . Criteria. ®. What Is R-SCAN?. 2. C. ollaborative activity . for referring clinicians and radiologists to improve patient . Dr. William Brant, . M.D., F.A.C.S., F.E.C.S.M.. Medical Degree. University of California. Internship & Residency. University of Colorado Health Sciences Center. Fellowship. Focusing on sexual medicine and surgery at University of California, San Francisco under the direction of Dr. Tom Lue. .  . Dr.Thabat. J. Al-. Maiahy. MBChB,DOG,CABOG. Radiotherapy. EXTERNAL RADIATION THERAPY. Indicated when an area to be irradiated is large, . e.g. cx cancer . The basic tent of radiation therapy is to maximize the tumor damage while minimizing the . 1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, et al. JAMA . Oncol. . 2015; 1(4): 505-27/ 2. . Droz. JP, et al. Lancet . Oncol. . 2014; 15(9): e404-14/ 3. . Cuzick. J, et al. Lancet . . By Dr. . Hiralal. . Chaudhari. M.B.B.S., D.N.B. (General Surgery). D.N.B. (Urology). Foundation Medicine. ctDNA. is good information for somatic mutations in . mCRPC. when biopsy is not possible. lots of other data on the importance of CTCs as predictive. 93% concordance for BRCA1/2 for tissue and liquid biopsy – . . 5. th. most commonly diagnosed cancer in Australia. 8.9% of new cancer diagnoses. In 2009: . 10,193 cases (. 6034 . men, 4159 women). Projection to . 2020.  . 13,640. Mortality. In 2010 most common cause of cancer death.